US2024009175A9PendingUtilityA9
Tetrazole derivatives
Est. expiryMar 19, 2040(~13.6 yrs left)· nominal 20-yr term from priority
A61K 31/437C07D 471/04A61K 31/444A61K 31/506A61K 31/501A61K 47/02A61K 9/02A61K 47/44A61K 9/08A61K 41/17A61K 9/06A61K 9/2059A61K 9/2013A61K 9/2813A61K 9/2826A61K 9/286A61K 9/4825A61K 9/19C07B 2200/05C07D 403/04C07D 403/14A61P 35/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
Claims
exact text as granted — not AI-modified1 : A tetrazole derivative of formula I-a, I-b, or I-c:
wherein independently from each other
R 1 denotes Ar A or Hetar A ;
R 2 denotes Ar B or Hetar B ;
R 3 denotes C 1-6 -aliphatic or —O—C 1-6 -aliphatic;
R 4 denotes H, D, C 1-6 -aliphatic, or —O—C 1-6 -aliphatic;
R 5 denotes H, D, C 1-6 -aliphatic, —O—C 1-6 -aliphatic, or halogen;
Ar A is a mono- or biaryl with 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms, wherein Ar A may be unsubstituted or substituted with substituents R A1 , R A2 , R A3 , R A4 , and/or R A5 which may be the same or different;
Ar B is a mono- or biaryl with 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms, wherein Ar B may be unsubstituted or substituted with substituents R B1 , R B2 , R B3 , R B4 , and/or R B5 which may be the same or different;
Hetar A is a mono- or bicyclic heteroaryl with 5, 6, 7, 8, 9, 10, or 11 ring atoms, wherein 1, 2, 3, 4, or 5 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O, and S, and the remaining ring atoms are carbon atoms, wherein Hetar A may be unsubstituted or substituted with substituents R A1 , R A2 , R A3 , R A4 , and/or R A5 which may be the same or different;
Hetar B is a mono- or bicyclic heteroaryl with 5, 6, 7, 8, 9, 10, or 11 ring atoms, wherein 1, 2, 3, 4, or 5 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O and S, and the remaining ring atoms are carbon atoms, wherein Hetar B may be unsubstituted or substituted with substituents R B1 , R B2 , R B3 , R B4 and/or R B5 which may be the same or different;
R A1 , R A2 , R A3 , R A4 , R A5 , R B1 , R B2 , R B3 , R B4 , R B5 are independently from each other H, D, halogen, C 1-6 -aliphatic, or —O—C 1-6 -aliphatic; and
halogen denotes F, Cl, Br, or I;
or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios.
2 : The tetrazole derivative according to claim 1 ,
wherein R 1 and R 2 are the same.
3 : The tetrazole derivative according to claim 1 ,
wherein R 1 and R 2 are different.
4 : The tetrazole derivative according to claim 1 ,
wherein Ar A is phenyl which may be unsubstituted or mono- or di-substituted with R A1 and/or R A2 ; Ar B is phenyl which may be unsubstituted or mono- or di-substituted with R B1 and/or R B2 ; Hetar A is a monocyclic heteroaryl with 5 or 6 ring atoms, wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O, and S, and the remaining ring atoms are carbon atoms, wherein Hetar A may be unsubstituted or substituted with substituents R A1 and/or R A2 which may be the same or different; and Hetar B is a monocyclic heteroaryl with 5 or 6 ring atoms, wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O, and S, and the remaining ring atoms are carbon atoms, wherein Hetar B may be unsubstituted or substituted with substituents R B1 and/or R B2 which may be the same or different.
5 : The tetrazole derivative according to claim 4 ,
wherein R A1 , R A2 , R B1 , R B2 are independently from each other H, F, Cl, C 1-4 -aliphatic, or —O—C 1-4 -aliphatic.
6 : The tetrazole derivative according to claim 1 ,
wherein independently from each other R 3 denotes substituted or unsubstituted C 1-4 -alkyl; R 4 denotes H; and R 5 denotes H, C 1-4 -alkyl, —O—C 1-4 -alkyl, F, or Cl.
7 : The tetrazole derivative according to claim 1 ,
wherein independently from each other R 3 denotes methyl, ethyl, 2-aminoethyl, or 2-hydroxyethyl; R 4 denotes H; R 5 denotes H, methyl, ethyl, methoxy, F, or Cl; Ar A is phenyl; deuterophenyl; flurophenyl; methylphenyl (tolyl); difluoromethoxy; or 4-difluoromethoxy-2-fluorophenyl; Ar B is phenyl; deuterophenyl; flurophenyl; methylphenyl (tolyl); difluoromethoxy; or 4-difluoromethoxy-2-fluorophenyl; Hetar A is methylpyrazolyl; thien-2-yl, thien-3-yl; methylthienyl; thiazolyl; pyridin-2-yl, pyridin-3-yl, pyridin-4-yl; pyrimidinyl; or pyridazinyl; and Hetar B is methylpyrazolyl; thien-2-yl, thien-3-yl; methylthienyl; thiazolyl; pyridin-2-yl, pyridin-3-yl, pyridin-4-yl; or pyridazinyl.
8 : The tetrazole derivative according to claim 1 ,
wherein the tetrazole derivative is selected from the group consisting of:
Compound
No.
Structure
Name
1
[3.7-diethyl-6-(1H-1,2,3,4-tetrazol-5- yl)imidazo[1.2-a]pyridin-2- yl]diphenylmethanol
2
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]- diphenyl-methanol
3
[3-Ethyl-7-fluoro-6-(1H-tetrazol-5- yl)-imidazo[1,2-a]pyridin-2-yl] diphenyl-methanol
4
[3-Ethyl-6-(1H-tetrazol-5-yl)- imidazo[1,2-a]pyridin-2-yl]- diphenyl-methanol
5
[7-Chloro-3-ethyl-6-(1H-tetrazol-5- yl)-imidazo[1,2-a]pyridin-2-yl]-bis- (2-fluoro-phenyl)-methanol
6
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl- bis-(2-fluoro-phenyl)-methanol
7
[7-chloro-3-ethyl-6-(1H-tetrazol-5- yl)imidazo[1,2-a]pyridin-2-yl]- phenyl-(2-pyridyl)methanol
8
[7-chloro-3-ethyl-6-(1H-tetrazol-5- yl)imidazo[1,2-a]pyridin-2-yl]- pbenyl-(2-pyridyl)methanol
9
[7-Chloro-3-ethyl-6-(1H-tetrazol-5- yl)-imidazo[1,2-a]pyridin-2-yl]- diphenyl-methanol
10
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]- phenyl-pyridin-2-yl-methanol
11
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]- phenyl-pyridin-2-yl-methanol
12
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]-(5- methyl-thiophen-2-yl)-phenyl- methanol
13
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]-(5- methyl-thiophen-2-yl)-phenyl- methanol
14
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]- phenyl-pyrimidin-2-yl-methanol
15
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]- phenyl-pyrimidin-2-yl-methanol
16
[3-ethyl-7-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)imidazo[1,2-a]pyridin- 2-yl](phenyl)[1,3-thiazol-2- yl)methanol
17
[3-Ethy]-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl]-(1- methyl-1H-pyrazol-3-yl)-phenyl- methanol
18
[3-Ethyl-7-methoxy-6-(1H-tetrazol- 5-yl)-imidazo[1,2-a]pyridin-2-yl-(1- methyl-1H-pyrazol-3-yl)-phenyl- methanol
19
[3-Ethyl-6-methoxy-5-(1H-tetrazol- 5-yl)-pyrazolo[1,5-a]pyridin-2-yl]- bis-(2-fluoro-phenyl)-methanol
20
[6-Chloro-3-ethyl-5-(1H-tetrazol-5- yl)-pyrazolo[1,5-a]pyridin-2-yl]-bis- (2-fluoro-phenyl)-methanol
21
[6-Chloro-3-ethyl-5-(1H-tetrazol-5- yl)-pyrazolo[1,5-a]pyridin-2-yl]- diphenyl-methanol
22
[3-Ethyl-6-methoxy-5-(1H-tetrazol- 5-yl)-pyrazolo[1,5-a]pyridin-2-yl]- diphenyl-methanol
23
[3-Ethyl-6-fluoro-5-(1H-tetrazol-5- yl)-pyrazolo[1,5-a]pyridin-2-yl]- diphenyl-methanol
24
[5-methoxy-1-methyl-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]diphenylmethanol
25
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyrimidin-4- yl)methanol
26
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](pyridin-2- yl)(thiophen-2-yl)methanol
27
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridazin-3- yl)methanol
28
[1-(2-aminoethyl)-5-methoxy-6-(1H- 1,2,3,4-tetrazol-5-yl)-1H- imidazo[4,5-b]pyridin-2- yl]diphenylmethanol
29
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(thiophen-3- yl)methanol
30
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)thiophen-3- yl)methanol
31
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(1,3-thiazol- 2-yl)methanol
32
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(1,3-thiazol- 2-yl)methanol
33
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(1,3-thiazol- 2-yl)methanol
34
2-[2-(hydroxy-diphenylmethyl)-5- methoxy-6-(1H-1,2,3,4-tetrazol-5- yl)-1H-imidazo[4,5-b]pyridin-1- yl]ethan-1-ol
35
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(thiophen-2- yl)methanol
36
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](1-methyl-1H- pyrazol-4-yl)phenylmethanol
37
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyrimidin-2- yl)methanol
38
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(thiophen-2- yl)methanol
39
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(2- methylphenyl)methanol
40
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridin-2- yl)methanol
41
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridin-2- yl)methanol
42
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](2- methylphenyl)phenylmethanol
43
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridin-4- yl)methanol
44
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridin-3- yl)methanol
45
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]diphenylmethanol
46
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(2- fluorophenyl)methanol
47
[4-(difluoromethoxy)-2- fluorophenyl][1-ethyl-5-methoxy-6- (1H-1,2,3,4-tetrazol-5-yl)-1H- imidazo[4,5-b]pyridin-2- yl]phenylmethanol
48
[4-(difluoromethoxy)-2- fluorophenyl][1-ethyl-5-methoxy-6- (1H-1,2,3,4-tetrazol-5-yl)-1H- imidazo[4,5-b]pyridin-2- yl]phenylmethanol
49
[4-(difluoromethoxy)-2- fluorophenyl][1-ethyl-5-methoxy-6- (1H-1,2,3,4-tetrazol-5-yl)-1H- imidazo[4,5-b]pyridin-2- yl]phenylmethanol
50
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](phenyl)(pyridin-2- yl)methanol
51
[5-chloro-1-ethyl-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]diphenylmethanol
52
[4-(difluoromethoxy)phenyl][1- ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl](2- fluorophenyl)methanol
53
[4-(difluoromethoxy)phenyl][1- ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]phenylmethanol
54
[4-(difluoromethoxy)-2- fluorophenyl][1-ethyl-5-methoxy-6- (1H-1,2,3,4-tetrazol-5-yl)-1H- imidazo[4,5-b]pyridin-2-yl](2- fluorophenyl)methanol
55
[1,5-dimethyl-6-(1H-1,2,3,4-tetrazol- 5-yl)-1H-imidazo[4,5-b]pyridin-2- yl]bis(2-fluorophenyl)methanol
56
[1,5-dimethyl-6-(1H-1,2,3,4-tetrazol- 5-yl)-1H-imidazo[4,5-b]pyridin-2- yl]diphenylmethanol
57
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(2- fluorophenyl)methanol
58
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]diphenylmethanol
59
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis(2- fluorophenyl)methanol
60
[1-ethyl-6-(1H-1,2,3,4-tetrazol-5-yl)- 1H-imidazo[4,5-b]pyridin-2- yl]diphenylmethanol
61
[1-ethyl-6-(1H-1,2,3,4-tetrazol-5-yl)- 1H-imidazo[4,5-b]pyridin-2-yl]bis(2- fluorophenyl)methanol
62
[1-ethyl-5-methyl-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]diphenylmethanol
63
[1-ethyl-5-methoxy-6-(1H-1,2,3,4- tetrazol-5-yl)-1H-imidazo[4,5- b]pyridin-2-yl]bis[(2,3,4,5,6- 2 H5)phenyl]methanol
9 : A medicament, comprising:
the tetrazole derivative according to claim 1 , or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios.
10 : A method, comprising:
treating a medical condition or disease that is affected by inhibiting ACSS2, with the tetrazole derivative according to claim 1 , or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios.
11 : A method, comprising:
treating a medical condition or disease, with the tetrazole derivative according to claim 1 , or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios, wherein the medical condition or disease is selected from the group consisting of cancer; an inflammatory disorder or disease, ulcerative colitis, idiopathic pulmonary fibrosis, muscular dystrophy, rheumatoid arthritis, systemic sclerosis; a neurogenerative disorder or disease; Lipid metabolism disorders, non-alcoholic fatty liver disease, fatty liver disease; a viral infection; post-traumatic stress disorder; bipolar disorder, depression, Tourettes's Syndrome, schizophrenia, obsessive-compulsive disorder, anxiety disorder, a panic disorder, a phobia, addiction, an impulse control disorder, and a behavioral addiction.
12 : A pharmaceutical composition, comprising:
at least one tetrazole derivative according to claim 1 , or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios, as active ingredient, and a pharmaceutically acceptable carrier.
13 : The pharmaceutical composition according to claim 12 , further comprising:
a second active ingredient or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof as well as a pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios, wherein the second active ingredient is not the tetrazole derivative of claim 1 .
14 : A set (kit), comprising separate packs of:
an effective amount of the tetrazole derivative of claim 1 , or any derivative, N-oxide, prodrug, solvate, tautomer, or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including a mixture thereof in all ratios; and an effective amount of a further active ingredient, wherein the further active ingredient is not the tetrazole derivative of claim 1 .
15 : A process for manufacturing the tetrazole derivative of formula I-a, I-b, or I-c according to claim 1 , the process comprising:
(a) reacting, in a cyclization reaction, a carbonitrile of general formula II-a
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ,
with a suitable azide reagent, optionally in the presence of a suitable catalyst, to yield the tetrazole derivative of formula I-a:
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ; or
(b) reacting, in a cyclization reaction, a carbonitrile of general formula II-b
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ,
with a suitable azide reagent, optionally in the presence of a suitable catalyst, to yield the tetrazole derivative of formula I-b:
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ; or
(c) reacting, in a cyclization reaction, a carbonitrile of general formula II-c
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ,
with a suitable azide reagent, optionally in the presence of a suitable catalyst, to yield the tetrazole derivative of formula I-c:
wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 .
16 : A carbonitrile of formula II-a, II-b, or II-c:
wherein independently from each other
R 1 denotes Ar A or Hetar A ;
R 2 denotes Ar B or Hetar B ;
R 3 denotes C 1-6 -aliphatic or —O—C 1-6 -aliphatic;
R 4 denotes H, D, C 1-6 -aliphatic, or —O—C 1-6 -aliphatic;
R 5 denotes H, D, C 1-6 -aliphatic, —O—C 1-6 -aliphatic, or halogen;
Ar A is a mono- or biaryl with 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms, wherein Ar A may be unsubstituted or substituted with substituents R A1 , R A2 , R A3 , R A4 , and/or R A5 which may be the same or different;
Ar B is a mono- or biaryl with 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms, wherein Ar B may be unsubstituted or substituted with substituents R B1 , R B2 , R B3 , R B4 , and/or R B5 which may be the same or different;
Hetar A is a mono- or bicyclic heteroaryl with 5, 6, 7, 8, 9, 10, or 11 ring atoms, wherein 1, 2, 3, 4, or 5 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O, and S, and the remaining ring atoms are carbon atoms, wherein Hetar A may be unsubstituted or substituted with substituents R A1 , R A2 , R A3 , R A4 and/or R A5 which may be the same or different;
Hetar B is a mono- or bicyclic heteroaryl with 5, 6, 7, 8, 9, 10, or 11 ring atoms, wherein 1, 2, 3, 4, or 5 of said ring atoms is/are a hetero atom(s) selected from the group consisting of N, O and S, and the remaining ring atoms are carbon atoms, wherein Hetar B may be unsubstituted or substituted with substituents R B1 , R B2 , R B3 , R B4 and/or R B5 which may be the same or different;
R A1 , R A2 , R A3 , R A4 , R A5 , R B1 , R B2 , R B3 , R B4 , R B5 are independently from each other H, D, halogen, C 1-6 -aliphatic, or —O—C 1-6 -aliphatic; and
halogen denotes F, Cl, Br, or I.
17 : The tetrazole derivative according to claim 7 , wherein
Ar A and/or Ar B is pentadeuterophenyl, 2-fluorophenyl, 2-methylphenyl, or 4-difluoromethoxy, and Hetar A and/or Hetar B is 1-methlypyrazol-3-yl, 1-methylpyrazol-4-yl, 5-methylthien-2-yl, 1,3-thiazol-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyridazin-3-yl.
18 : The method according to claim 11 , wherein the medical condition or disease is selected from the group consisting of a tumor; Crohn's disease; Huntington's disease; non-alcoholic steatohepatitis; a viral infection with cytomegalovirus; and addiction to alcohol, tobacco, an opioid, a sedative, a hypnotic, an anxiolytic, cocaine, cannabis, an amphetamine, a hallucinogen, an inhalant, or phencyclidine.Join the waitlist — get patent alerts
Track US2024009175A9 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.